+44 (0) 1223 755950
+1 832 327 7413
Farletuzumab ELISA Kit
REQUEST MORE INFO
Catalogue No: abx395074
Price:
US$942.50
(Size: 96 tests)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Farletuzumab ELISA Kit is a quantitative ELISA kit for detection of Farletuzumab.Farletuzumab (MORAb-003) is a humanized α-FR-targeted monoclonal antibody derived from the murine antibody, LK26 (Teng, Xie, Teng, & Lee, 2012). In preclinical studies, farletuzumab elicited robust antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, thus inhibiting the growth of human ovarian tumor xenografts (Teng et al., 2012). Farletuzumab combined with carboplatin and taxane may enhance the response rate and duration of response in patients with platinum-sensitive ovarian cancer with first relapse after remission duration of 6–18 months (Konner et al., 2010). Based on these encouraging findings, a Phase III study was undertaken in patients with platinum-sensitive recurrent ovarian cancer (Walters et al., 2013). The FAR131 trial did not prove efficacy for patients with platinum-sensitive ovarian cancer (PSOC, defined as a PFI of ≥ 6 months), in terms of the primary endpoint of PFS. Aside from Farletuzumab, other antibodies have been developed to target FR, and tested clinically. Similar to studies exploiting Vintafolide, a Phase III, open-label, randomized study (ClinicalTrials.gov Identifier: NCT02631876) was designed to compare the safety and efficacy of Mirvetuximab soravtansine, also known as IMGN853, an α-FR-targeting antibody-drug conjugate, to that of selected single-agent chemotherapies in women with platinum-resistant α-FR-positive advanced EOC, and other pelvic cancers. The antibody serves to specifically target the highly potent microtubule inhibitor maytansinoid DM4 to the α-FR-positive cancer cells. In addition, vaccines against FR have been produced and evaluated, such as the folate-binding protein vaccines E39 and J65 involved in the Phase Ib trial (ClinicalTrials.gov Identifier: NCT02019524) for patients with breast or ovarian cancer diagnosis who have been treated and are without evidence of disease. A Phase II clinical trial (NCT02764333) is testing on patients with Pt-resistant ovarian cancer the safety and effectiveness of two investigational drugs, TPIV200/huFR-1 (also called TPIV200), a vaccine consisting of proteins from α-FR mixed with GM-CSF, and durvalumab (MEDI4736).
Research Articles on Farletuzumab
| Target | Farletuzumab |
| Reactivity | Human |
| Tested Applications | ELISA |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Storage | Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual. |
| Validity | The validity for this kit is 6 months. |
| Stability | The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5% within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout. |
| Test Range | 0.31 μg/ml - 5 μg/ml |
| Sensitivity | 0.16 μg/ml |
| Standard Form | Lyophilized |
| Detection Method | Colorimetric |
| Assay Type | Competitive |
| Assay Data | Quantitative |
| Sample Type | Serum and plasma. |
| CAS Number | 896723-44-7 |
| Availability | Shipped within 10-20 working days. |
| Note | This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein. |